Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Different Profiles of Spatial Navigation Deficits In Alzheimer's Disease Biomarker-Positive Versus Biomarker-Negative Older Adults With Amnestic Mild Cognitive Impairment

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F22%3A00077663" target="_blank" >RIV/00159816:_____/22:00077663 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/00064203:_____/22:10444667 RIV/00216208:11130/22:10444667

  • Výsledek na webu

    <a href="https://www.frontiersin.org/articles/10.3389/fnagi.2022.886778/full#h10" target="_blank" >https://www.frontiersin.org/articles/10.3389/fnagi.2022.886778/full#h10</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3389/fnagi.2022.886778" target="_blank" >10.3389/fnagi.2022.886778</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Different Profiles of Spatial Navigation Deficits In Alzheimer's Disease Biomarker-Positive Versus Biomarker-Negative Older Adults With Amnestic Mild Cognitive Impairment

  • Popis výsledku v původním jazyce

    BackgroundSpatial navigation impairment is a promising cognitive marker of Alzheimer&apos;s disease (AD) that can reflect the underlying pathology. ObjectivesWe assessed spatial navigation performance in AD biomarker positive older adults with amnestic mild cognitive impairment (AD aMCI) vs. those AD biomarker negative (non-AD aMCI), and examined associations between navigation performance, MRI measures of brain atrophy, and cerebrospinal fluid (CSF) biomarkers. MethodsA total of 122 participants with AD aMCI (n = 33), non-AD aMCI (n = 31), mild AD dementia (n = 28), and 30 cognitively normal older adults (CN) underwent cognitive assessment, brain MRI (n = 100 had high-quality images for volumetric analysis) and three virtual navigation tasks focused on route learning (body-centered navigation), wayfinding (world-centered navigation) and perspective taking/wayfinding. Cognitively impaired participants underwent CSF biomarker assessment [amyloid-beta(1-42), total tau, and phosphorylated tau(181) (p-tau(181))] and amyloid PET imaging (n = 47 and n = 45, respectively), with a subset having both (n = 19). ResultsIn route learning, AD aMCI performed worse than non-AD aMCI (p &lt; 0.001), who performed similarly to CN. In wayfinding, aMCI participants performed worse than CN (both p &lt;= 0.009) and AD aMCI performed worse than non-AD aMCI in the second task session (p = 0.032). In perspective taking/wayfinding, aMCI participants performed worse than CN (both p &lt;= 0.001). AD aMCI and non-AD aMCI did not differ in conventional cognitive tests. Route learning was associated with parietal thickness and amyloid-beta(1-42), wayfinding was associated with posterior medial temporal lobe (MTL) volume and p-tau(181) and perspective taking/wayfinding was correlated with MRI measures of several brain regions and all CSF biomarkers. ConclusionAD biomarker positive and negative older adults with aMCI had different profiles of spatial navigation deficits that were associated with posterior MTL and parietal atrophy and reflected AD pathology.

  • Název v anglickém jazyce

    Different Profiles of Spatial Navigation Deficits In Alzheimer's Disease Biomarker-Positive Versus Biomarker-Negative Older Adults With Amnestic Mild Cognitive Impairment

  • Popis výsledku anglicky

    BackgroundSpatial navigation impairment is a promising cognitive marker of Alzheimer&apos;s disease (AD) that can reflect the underlying pathology. ObjectivesWe assessed spatial navigation performance in AD biomarker positive older adults with amnestic mild cognitive impairment (AD aMCI) vs. those AD biomarker negative (non-AD aMCI), and examined associations between navigation performance, MRI measures of brain atrophy, and cerebrospinal fluid (CSF) biomarkers. MethodsA total of 122 participants with AD aMCI (n = 33), non-AD aMCI (n = 31), mild AD dementia (n = 28), and 30 cognitively normal older adults (CN) underwent cognitive assessment, brain MRI (n = 100 had high-quality images for volumetric analysis) and three virtual navigation tasks focused on route learning (body-centered navigation), wayfinding (world-centered navigation) and perspective taking/wayfinding. Cognitively impaired participants underwent CSF biomarker assessment [amyloid-beta(1-42), total tau, and phosphorylated tau(181) (p-tau(181))] and amyloid PET imaging (n = 47 and n = 45, respectively), with a subset having both (n = 19). ResultsIn route learning, AD aMCI performed worse than non-AD aMCI (p &lt; 0.001), who performed similarly to CN. In wayfinding, aMCI participants performed worse than CN (both p &lt;= 0.009) and AD aMCI performed worse than non-AD aMCI in the second task session (p = 0.032). In perspective taking/wayfinding, aMCI participants performed worse than CN (both p &lt;= 0.001). AD aMCI and non-AD aMCI did not differ in conventional cognitive tests. Route learning was associated with parietal thickness and amyloid-beta(1-42), wayfinding was associated with posterior medial temporal lobe (MTL) volume and p-tau(181) and perspective taking/wayfinding was correlated with MRI measures of several brain regions and all CSF biomarkers. ConclusionAD biomarker positive and negative older adults with aMCI had different profiles of spatial navigation deficits that were associated with posterior MTL and parietal atrophy and reflected AD pathology.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30227 - Geriatrics and gerontology

Návaznosti výsledku

  • Projekt

    <a href="/cs/project/EF16_019%2F0000868" target="_blank" >EF16_019/0000868: Molekulární, buněčný a klinický přístup ke zdravému stárnutí</a><br>

  • Návaznosti

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Ostatní

  • Rok uplatnění

    2022

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Frontiers in Aging Neuroscience

  • ISSN

    1663-4365

  • e-ISSN

  • Svazek periodika

    14

  • Číslo periodika v rámci svazku

    June

  • Stát vydavatele periodika

    CH - Švýcarská konfederace

  • Počet stran výsledku

    24

  • Strana od-do

    nestrankovano

  • Kód UT WoS článku

    000811841400001

  • EID výsledku v databázi Scopus